BHVN Biohaven Pharmaceutical Holding Company Ltd

$BHVN regardless of what you think of this ticker and biotech this ceo is the best if not the best. The way he navigates the fda and doesn’t insight controversy and 🔥 fda counterparts, a collaboration you need to have on your side, there is no better. Compare to $CAPR $REPL et others

$BHVN What a battle---just too much volume for the shorts to push hard down. BULLS winning today!

$BHVN After reading the articles, im not getting too excited. They originally had great results showing 70% slow in progression of the didease, yet it was never approved. This makes me think there were either some other sideeffects that they did not want to disclose in the article OR was this more personal between the FDA and the company. The recent articles stressed new management, but the same team. LOTS of mixed signals, proceed with caution. Don't get too excited.

$BHVN $CAPR $REPL Have you done or have thoughts on which small / mid biotech companies do the best here?

$BHVN Great surprise news/update with several catalysts on the horizon. This one wasn't expected, but excitedly welcome. Important near-term catalysts: - Taldefgrobep alfa: Phase 2 obesity results expected in the second half of 2026. - Opakalim: Pivotal epilepsy results expected in the second half of 2026. - BHV-1530: New oncology data at ESMO in October. Bright future of opportunities for $BHVN. Cheers! $XBI

$BHVN Tomorrow is the esmo, then we have a few catalysts coming up soon: the fda hold, epilepsy data readout, obesity

$BHVN New Barid Upgrade from 42 to 48. Calls the SCA Drug update a surprise. I think it surprised everyone--but what a great surprise it was to know that we are closer to a commercialized drug with the H2 catalysts about to get started. For those new here, this is the calmer time before the real fireworks fly--we are about to get results of 2 placebo based trials.

$BHVN Guys please pump to 18+ again so I can reload my shorts been trading the short like crazy!

$BHVN $CAPR $REPL Why this wins! When CEO Vlad Coric at Biohaven ($BHVN) hit a setback with troriluzole (receiving a CRL for spinocerebellar ataxia), he didn't publicly pick a fight, flame regulators on earnings calls, or litigate through press releases. Instead, Biohaven pivoted focus onto its high-value pipeline (like its myostatin degrader) while quietly, methodically negotiating behind closed doors to re-engage the FDA.

$BHVN: FDA accepted Biohaven's Vyglxia NDA resubmission for review and set a first-quarter 2027 decision goal.

$BHVN This is what a successful ad-com for a Rare Disease Drug can do. • The Battle: Replimune was attempting a Class 1 resubmission for an advanced skin cancer drug (RP1). Like Biohaven, the market was highly skeptical of their trial design. • The AdCom Moment: On July 30, 2026, the FDA Cellular, Tissue, and Gene Therapies Advisory Committee met live. After a fierce debate, the independent medical panel voted 10 to 3 in favor of Replimune, stating the efficacy data was clinically meaningful. • The Reaction: The stock exploded.

$BHVN you will notice a lot of the times that before a very big increasing the price they need to manipulate the price and to lower it down scare everybody away purchase as much as they can cheap price and then the price go up I've seen this again and again only yesterday I saw it with two stocks xlab and another one and you will notice before and after hours there is a big big selling pressure and then buying pressure this is the same thing if you see a cheap price it's an opportunity to buy

FDA WATCH | October 22 $BHVN — FDA accepts Vyglxia resubmission for review, with an advisory committee meeting expected. $ABUS — FDA lifts AB-101 clinical hold, allowing further U.S. development for hepatitis B. Both treatments remain investigational.

$BHVN expect analyst upgrades and price target raises soon. This catalyst was another one of the wildcards that wasn't included in the models

$BHVN short sellers keep on covering by the way if you do 1 + 1 covering plus buying volume you get the hyperbolic horizontal move

$BHVN BHVN is surging, near 15.95, up about 36 percent, after the FDA accepted Biohaven's resubmission for Vyglxia, also known as troriluzole, in spinocerebellar ataxia. The FDA said it considers the resubmission a complete response to the November 2025 rejection letter and set a decision date in the first quarter of 2027. Biohaven says the filing includes new positive supportive analyses. There's a catch worth noting. The FDA also plans to convene an advisory committee meeting to get outside input, with a date to come. That's a real hurdle, because the original rejection pointed to concerns about bias, study design, and a lack of pre specified analyses in the supporting data. So this is a second chance, not an approval. Expect the advisory committee to be the next big swing factor. Follow me for more on the biotech names.

$BHVN I think everything was priced in at 9 dollars per share.... including everything in their pipeline....if you estimate dilution

$BHVN Wow, the shorts cane out in force on the board… lol. I smell FEAR. Could be a double if they release encouraging Obesity data. Be careful guys, this is now a very dangerous stock to play shortie in. GLTY

$BHVN Revenue $0 Quarterly net loss -$137.3 million Six-month net loss -$267.8 million Cash and marketable securities $267.9 million Debt (notes payable) $259.5 million Six-month operating cash burn $235 million

$BHVN gotta hand it to the shorts for their persistence. After last week's announcement, I thought we'd have no problem staying up and over $15 ... minimum. Both providers and paitents/families are desperate for some sort of treatment for SCA and I can't see anyway the adcom doesn't vote for approval given the very clean safety profile. Of course that still doesn't guarrantee approval but all the recent developments at the FDA sure point to a strong likelihood. Troriluzole ALONE would justify the current $14/share, ~$2B market cap. Guess it just means more upside later. I don't mind waiting.